Protective cardiac conditioning by an atypical cytokine

Ischemic heart disease (IHD) represents the leading cause of morbidity and mortality worldwide. Therapy options generally aim at restoring the blood flow to the heart muscle and relieve the ischemic insult. Paradoxically, coronary artery reperfusion itself, both during emergency intervention in ST s...

Full description

Saved in:
Bibliographic Details
Published inClinical science (1979) Vol. 133; no. 8; pp. 933 - 937
Main Author Bernhagen, Jürgen
Format Journal Article
LanguageEnglish
Published England 30.04.2019
Subjects
Animals
Humans
Ischemic Preconditioning
Macrophage Migration-Inhibitory Factors
Mice
Myocardial Ischemia
Myocardial Reperfusion Injury
Myocardium
cytokine
ischemic preconditioning
chemokine
myocardial infarction
ischemia
Online AccessGet full text

Cover

More Information
Summary:Ischemic heart disease (IHD) represents the leading cause of morbidity and mortality worldwide. Therapy options generally aim at restoring the blood flow to the heart muscle and relieve the ischemic insult. Paradoxically, coronary artery reperfusion itself, both during emergency intervention in ST segment elevation myocardial infarction (STEMI) patients or in the setting of elective cardiac surgery, damages the heart muscle, a phenomenon known as myocardial ischemia-reperfusion (I/R) injury (IRI). Ischemic preconditioning (IPC) is defined by episodes of 'sub-lethal' ischemia and reperfusion prior to prolonged coronary artery occlusion. It has been extensively studied as a promising approach to attenuate IRI, but two recent multicenter clinical trials of remote IPC (RIPC) on clinical outcomes have been disappointing. Macrophage migration-inhibitory factor (MIF) is a structurally unique chemokine-like inflammatory cytokine. MIF is pro-atherogenic, but has a complex function in the ischemic heart with a surprising potential as a local cardioprotective factor in early myocardial ischemia. A recent paper published in by Ruze et al. [9], now suggests that MIF could be a key player mediating IPC in the ischemic heart. Employing a gene knockout mouse model, the study indicates a role for endogenous MIF in IPC-mediated protection from myocardial IRI. It could assist in understanding how this atypical cytokine controls ischemic heart pathologies and may set the stage for novel MIF-based therapeutic strategies in IHD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:0143-5221
1470-8736
DOI:10.1042/CS20190036